Presentation is loading. Please wait.

Presentation is loading. Please wait.

(apoptotic + necrotic)

Published byMichael Wood Modified over 5 years ago

Similar presentations

Presentation on theme: "(apoptotic + necrotic)"— Presentation transcript:

1 (apoptotic + necrotic)
Untreated hIgG (crosslinked) Dacetuzumab (soluble) (crosslinked) Cell Death (Ramos) Percent Cell Death (apoptotic + necrotic) Dacetuzumab (crosslinked) Proliferation (Ramos) ng/ml b Dacetuzumab Signaling (RL) c phospho-ERK1/2 MAPK b-Actin 111 ng/ml Dacetuzumab Untreated 333 1.00x103 37.0 12.3 4.12 Ramos Dacetuzumab (soluble) (crosslinked) 1 3 10 20 Untreated hIgG (soluble) hIgG (crosslinked) Crosslinking Ab CD40 Ligand mg/ml phospho-AKT phospho-ERK1/2 MAPK IkB-a phospho-p38 MAPK Lane: 2 4 5 6 7 8 9 11 Supplementary Figure 1 Lewis, et al.

Download ppt "(apoptotic + necrotic)"

Similar presentations

P-ERK Total ERK Mel888 CHL1 WM793 0 10 50 BRAFi (nmol/L) Supplemental Figure 2: Other surface molecules unaffected ns PD-L1 ns MCSP DMSO BRAFi Supplemental.

P-ERK Total ERK Mel888 CHL1 WM BRAFi (nmol/L) Supplemental Figure 2: Other surface molecules unaffected ns PD-L1 ns MCSP DMSO BRAFi Supplemental.
P-ERK β-tubulin VSShh + cyclopamine Supplementary Figure ESM 1a ERK MAP Kinase activity is not affected by Shh pathway activity. Western blot analysis.

P-ERK β-tubulin VSShh + cyclopamine Supplementary Figure ESM 1a ERK MAP Kinase activity is not affected by Shh pathway activity. Western blot analysis.
Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%
A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) 0 5 10 20 Stat3:Stat3 % of Cont 100 56 43 1 Supplementary Figures Fig. S1 -

A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) Stat3:Stat3 % of Cont Supplementary Figures Fig. S1 -
1 ++++ ---- Dox E17K WT Basal mediumGrowth medium p-AKT S473 FLAG PI3K  p-AKT T308 p-mTOR S2448 p-mTOR S2481 mTOR Actin Davies BR et al. Supplementary.

Dox E17K WT Basal mediumGrowth medium p-AKT S473 FLAG PI3K  p-AKT T308 p-mTOR S2448 p-mTOR S2481 mTOR Actin Davies BR et al. Supplementary.
Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure1 0 0.03 0.3 3 30 (µM) 120 100 80 60 40 20 0 Penetratin control % of control 0 0.03 0.3 3 30 (µM) 120 100.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)
Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM
Figure S3 Young Cells Aged Cells *

Figure S3 Young Cells Aged Cells *
Supplementary figures

Supplementary figures
Copyright © 2010 American Medical Association. All rights reserved.

Copyright © 2010 American Medical Association. All rights reserved.
In Cardiomyocyte Hypoxia, Insulin-Like Growth Factor-I-Induced Antiapoptotic Signaling Requires Phosphatidylinositol-3-OH-Kinase-Dependent and Mitogen-Activated.

In Cardiomyocyte Hypoxia, Insulin-Like Growth Factor-I-Induced Antiapoptotic Signaling Requires Phosphatidylinositol-3-OH-Kinase-Dependent and Mitogen-Activated.
Suppression of ENTPD5 in human NSCLC cells results in decreased AKT activity and decreased proliferation under low-serum conditions. Suppression of ENTPD5.

Suppression of ENTPD5 in human NSCLC cells results in decreased AKT activity and decreased proliferation under low-serum conditions. Suppression of ENTPD5.
The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCθ and ERK pathways by Gilles Despouy, Marjorie Joiner, Emilie Le Toriellec,

The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCθ and ERK pathways by Gilles Despouy, Marjorie Joiner, Emilie Le Toriellec,
Antiproliferative effects of erlotinib correlate poorly with abundance of p-EGFR. Antiproliferative effects of erlotinib correlate poorly with abundance.

Antiproliferative effects of erlotinib correlate poorly with abundance of p-EGFR. Antiproliferative effects of erlotinib correlate poorly with abundance.
Volume 135, Issue 2, Pages e3 (August 2008)

Volume 135, Issue 2, Pages e3 (August 2008)
Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.
Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.

Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.
Western blots Kleinjan et al., “Drug-tunable multi-dimensional Synthetic Gene Control using Inducible Degron-tagged dCas9 Effectors”. dCas9 dCas9 GFP Histone.

Western blots Kleinjan et al., “Drug-tunable multi-dimensional Synthetic Gene Control using Inducible Degron-tagged dCas9 Effectors”. dCas9 dCas9 GFP Histone.
A B Supplementary Figure 3

A B Supplementary Figure 3
Autophagy: Paying Charon's Toll

Autophagy: Paying Charon's Toll

Similar presentations

Ads by Google